McKesson Corporation (MCK) Earnings Call Transcript & Summary

May 7, 2026

New York Stock Exchange US Health Care Health Care Providers and Services earnings 60 min

What were the key takeaways from McKesson Corporation's May 7, 2026 earnings call?

In the fourth quarter of fiscal 2026, McKesson Corporation reported consolidated revenues of $96.3 billion, a 6% increase year-over-year, and adjusted earnings per diluted share of $11.69, reflecting a 16% increase. The company also achieved full-year revenues of $403 billion, up 12%, and adjusted earnings per diluted share of $39.11, an 18% increase. Management provided guidance for fiscal 2027, projecting adjusted earnings per diluted share between $43.80 and $44.60, indicating a year-over-year growth of 12% to 14%. This guidance reflects strong momentum across their strategic growth platforms and a disciplined approach to capital deployment.

What topics did McKesson Corporation cover?

  • Strong Revenue Growth: McKesson's consolidated revenues for Q4 reached $96.3 billion, which is a 6% increase year-over-year. This growth was attributed to broad-based demand across the portfolio, particularly in specialty pharmaceutical distribution and oncology. Management stated, "Earnings per diluted share were $11.69, a 16% increase over the prior year."
  • Successful Strategic Acquisitions: The acquisitions of PRISM and Core Ventures contributed significantly to McKesson's growth, with the oncology and multispecialty segment revenues increasing by 35% to $12.7 billion. Management noted that these acquisitions contributed approximately 13% to this growth, highlighting their successful integration.
  • Cash Flow and Shareholder Returns: McKesson generated free cash flow of $5.4 billion in fiscal 2026, exceeding guidance due to strong operational performance. The company returned $5.1 billion to shareholders, including $2.25 billion through an accelerated share repurchase program, demonstrating their commitment to returning capital to shareholders.
  • Guidance for Fiscal 2027: Management provided guidance for fiscal 2027, projecting adjusted earnings per diluted share between $43.80 and $44.60, which represents a growth of 12% to 14%. This guidance reflects confidence in sustained operating momentum and disciplined execution across their strategic initiatives.
  • Impact of Pricing Changes: Management acknowledged that branded pharmaceutical pricing declines impacted revenue growth, particularly in the North American Pharmaceutical segment. They stated, "the impact of branded pricing declines...reduced year-over-year revenue growth by approximately 3% in the quarter."

What were McKesson Corporation's May 7, 2026 results?

  • Revenue: $96.3 billion (+6% YoY)
  • Adjusted EPS: $11.69 (+16% YoY)
  • Full Year Revenue: $403 billion (+12% YoY)
  • Adjusted Operating Profit: $6.5 billion (+15% YoY)
  • Free Cash Flow: $5.4 billion
  • Shareholder Returns: $5.1 billion

McKesson's strong performance in fiscal 2026, marked by significant revenue growth and operational efficiency, positions the company favorably for fiscal 2027. The guidance provided indicates continued confidence in their strategic initiatives and growth potential. However, investors should monitor the impacts of pricing changes and the evolving competitive landscape in the pharmaceutical distribution space as potential risks.

Earnings Call Speaker Segments

Jeni Dominguez

executive
#1

Thanks, operator. Good afternoon, everyone, and welcome to McKesson's call covering results for the fourth quarter of fiscal 2026. With me today are Brian Tyler, who serves as our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. Brian goes first, Britt follows him, and after that we'll open things up for questions and answers. During today's discussion, we'll be making forward-looking statements, including forecasts regarding McKesson's operations and results in the future. I'd ask you to review the cautionary statements contained in today's earnings release and the presentation slides, which you can find on our website at investor.mckesson.com, along with the Risk Factors section of our latest annual and periodic SEC filings, for additional details about risk factors that might cause our actual results to differ materially from what those forward-looking statements suggest. Details on GAAP and non-GAAP financial measures that we'll cover during this webcast, including a reconciliation of those measures to GAAP results, are available in today's earnings release and presentation slides. The presentation slides also contain a summary of our quarterly results and our guidance assumptions; so with that, I'll hand things over to Brian.

Brian Tyler

executive
#2

Thank you, Jeni. Good afternoon, everyone, and thank you for being here on McKesson's call covering results for the fiscal fourth quarter. We shared earlier today that we closed out a solid fourth quarter, wrapping up a year of impressive results; during fiscal 2026, our adjusted earnings per diluted share climbed 18%, powered by forward motion throughout our strategic growth platforms. Operating cash flow came in at $6.2 billion, a robust figure that beat what we had planned. To our shareholders, we gave back $5.1 billion. . Fiscal '26 represented yet another excellent stretch of execution along with disciplined portfolio moves that hone where we concentrate and generated sustained operating momentum. As the year got underway, Core Ventures and PRISM Vision joined our oncology platform and our multi-specialty platform. Each of these businesses was brought aboard without friction, producing robust growth momentum while broadening high-quality care delivered in community settings. Twelve months ago, we laid out the plan to spin off our Medical Surgical Solutions segment as a standalone company. From that point forward, we have achieved meaningful headway toward this goal. Transition service agreements have been established, financing transactions were carried out, and we signed an agreement welcoming Apollo as an investor holding a minority interest, all while pushing forward the separation readiness of the business. As we keep working toward the separation we have planned, we hold strong confidence that it will free up shareholder value and bring strategic clarity to each organization. During January, we finished our exit from Norway, maintaining our disciplined method of optimizing the portfolio and meeting our pledge to fully leave the European business behind. On the operational side, we took steps to bring our organizational structure into closer alignment with our strategy. New reporting segments were introduced, which opened up greater transparency into our growth areas and improved how reporting lines up with the way we run the business and direct capital. Our work on these strategic initiatives generated the robust results we posted in fiscal '26 and leaves us favorably positioned for fiscal '27. Turning to what's ahead, we expect adjusted earnings per diluted share within a range of $43.80 to $44.60 for fiscal '27. With a portfolio sharply focused on strategy, a solid balance sheet and an operating model that is clear, we are positioned well to generate long-term value for shareholders as we carry out the essential role we hold throughout the health care value chain. Now I'd like to walk you through how our company priorities are shaping McKesson's future. I'll begin with people and culture, still the essential enabler behind all that we do. The environment we work in is complex and changing fast, and shaping our future means we must keep evolving the way we lead while staying rooted in our values and our mission. We bring this into our culture through our IQ Care principles, which capture our values: integrity, inclusion, customer-first respected excellence, and also through LeadRx, our leadership principles. Combined, these form our leadership prescription framework; it strengthens accountability, trust and a commitment to serving our customers. LeadRx sets a shared standard that guides bold choices, delivers outcomes that matter at speed and builds the teams of tomorrow. Team McKesson's demonstration of those leadership behaviors never fails to inspire me. Two people deserve recognition today for being outstanding allies both to me and to our leadership team. We shared news during the quarter about Bricks' planned retirement. Throughout his time here, he was instrumental in reinforcing McKesson's financial base, pushing forward our capital deployment framework, and putting the company in position for sustainable long-term growth. Disciplined clarity and a steadfast commitment to creating shareholder value have defined his leadership. Brick leaves behind a robust, deep finance organization that will keep serving the company far into the future. I'd be overlooking something important if I failed to mention that under Britt's leadership as CFO, shareholder returns rose by more than 500%. That works out to an annual growth rate above 20%. Thank you, Britt. We're also sharing Board changes today. Don Kanouse will wrap up his service on our Board ahead of the 2026 Annual Stockholder Meeting in July, in line with the age guidelines for our outside directors. My thanks go to Don for his dependable leadership and meaningful contributions as our Board's independent Chair. As of May 1, I was elected Chairman of our Board, serving alongside Dominic Caruso, who brings 7 years of experience on McKesson's Board and will take on the role of lead independent director, ensuring we maintain strong independent oversight going forward. Now I'd like to turn to our strategic pillars. Let's begin with oncology and the multi-specialty platform. Specialty medications keep showing robust growth, and we're putting our differentiated solutions portfolio to work improving access, helping providers in the community, and giving biopharma customers valuable data and insights. It's gratifying to watch these platforms keep expanding; for the U.S. oncology network, growth this year has been remarkable. We brought on over 570 providers in fiscal '26, the biggest net gain since 2010; in April, our footprint grew further when Cancer Care Northwest joined us, with clinic locations spanning Washington and Idaho. We keep applying our capabilities and bringing core ventures onto our platform. Take Tata, our data and insights business, which is now folding in in-office dispensing data from Florida Cancer Specialist and Research Institute. That widens the data we offer biopharma customers so they can better gauge adoption and performance trends throughout the broader community oncology landscape. As the platform scales, we're building in automation and AI to streamline workflow and elevate the patient experience. Across the U.S. oncology network, ambient scribe technology now has more than 1,900 providers using it. That frees them to devote more time to patients and less to documentation, letting them do the work they trained for; these capabilities show how data, technology, and scale are being used to substantially boost our physicians' productivity and free up more time for care delivery. On our retina and ophthalmology side, PRISM Vision grew its provider count by roughly 20% during the last twelve months, and we added two practices: OKI Clinic and, more recently in May, the Retina Macula Institute, which pushes our reach past the Mid-Atlantic area. Now turning to biopharma services. Our fourth fiscal quarter tends to be the peak period, since that's when we help patients complete their yearly verifications. This time around, we had our best season ever, guiding a record 3.4 million patients as they worked to obtain the medications they require. That came from solid execution, careful planning, and ongoing investments in productivity, such as deploying technology and automation. Because of this, every full-time employee served 120 additional patients this season versus the prior year. We're happy with the ongoing momentum in the business, which a differentiated, scaled network underpins — we're digitally linked to more than 50,000 pharmacies, over 1 million providers, and we serve more than 650 biopharma brands spanning most therapeutic areas. During the last year, we assisted patients in saving about $10 billion on brand and specialty medications, most of which involved non-GLP-1 drugs. We stopped an estimated 12 million prescriptions from being abandoned because of affordability issues, and we make it possible for patients to get their medicines over 135 million times.

Brian Tyler

executive
#3

With this scale and ongoing momentum as our foundation, we keep putting money back into the company to push forward our strategic emphasis on technology-enabled services. The aim of these investments is to boost product capabilities, elevate how customers experience our offerings, and bring in more automation. Not long ago, we introduced an industry-first set of integrated specialty access and affordability solutions, built to tackle the fragmentation that frequently holds up the beginning of a treatment. By linking benefits verification, prior authorization, and affordability support within one coordinated workflow, this offering assists manufacturers in speeding up time to therapy for medications that are high-cost and high-touch. That stands as a strong illustration of how our scale and technology are being used to back biopharma customers in the places where access is most critical. Moving to North American distribution; our attention stays on operational excellence and long-term sustainability as we keep building a distribution platform that is more resilient and scalable. Not long ago, we hit an important milestone by successfully opening our new Montreal distribution center. As a piece of our supply chain of the Future initiative, this cutting-edge facility adds vital capacity and comes with industry-leading automation, among it an advanced storage and retrieval system driven by AI and robots, which lifted the bar for precision and performance. When it is fully ramped, this facility will boost resiliency, sharpen service reliability throughout Eastern Canada, and strengthen our capacity to serve customers and patients with more speed, consistency, and efficiency. Throughout our supply chain, AI-driven inventory planning capabilities are assisting us in shifting from reactive decision-making to real-time decision-making that is more technology-enabled. We brought in an advanced planning system that applies AI to link and orchestrate end-to-end planning spanning demand, supply, inventory, and operations within one integrated environment. This transformation lets us produce working capital savings and made a meaningful contribution to the strong operating cash flow in fiscal 2026. Since we run a scaled network that distributes roughly 1/3 of pharmaceuticals in North America, we take considerable pride in safeguarding the resiliency of our supply chain; in January, a significant winter weather event across more than 20 states put strain on transportation networks. Thanks to early risk monitoring, proactive planning, and strong execution, we kept operations safe and reduced disruptions to our customers and their patients. This is one more instance that highlights the strength and reliability of our operating model and our dedication to excellent service; in the past quarter, we successfully navigated the first wave of branded pharmaceutical price changes related to the Inflation Reduction Act. As anticipated, revenue growth took a hit, but the fundamentals of our business and the strength of our value proposition to manufacturers stay very strong, as shown by the double-digit adjusted segment operating profit growth in fiscal '26. We keep managing the business with discipline, making sure we receive appropriate compensation for the critical services we provide, which sets us up well for sustained long-term growth; we're operating in a dynamic policy environment. McKesson has a unique role to play, collaborating with policymakers and advocating for changes that advance health care for all. We're confident that our differentiated capabilities will continue to position us to evolve with the market and to enable better outcomes. Let me give you a quick rundown of what we've been doing with the portfolio. Back in April, we hit a key milestone on the path toward separating medical surgical solutions. Two financing deals got done — a senior secured Term Loan A worth $1 billion, plus a revolving credit facility also at $1 billion. The point of these is to put a stand-alone capital structure in place for that business, which helps with separation readiness and gives NewCo financial flexibility once it's operating independently. On top of that, we shared news of a definitive agreement with Apollo Funds involving a $1.25 billion strategic minority investment into Medical Surgical Solutions — that works out to roughly a 13% minority interest and puts NewCo's total enterprise value at about $13 billion. Regulatory approvals and customary closing conditions still apply, and we'll keep operating control along with majority ownership, while gaining the benefit of Apollo's know-how in handling complicated carve-outs and public market transactions. That marks one more significant step as we move into the next phase of the separation and get ready for the planned IPO, with our eyes firmly on maximizing shareholder value. Let me wrap up here. McKesson just posted another year of strong operational results, which speaks to the strength of our growth strategy, the worth of our differentiated portfolio, and how disciplined we've been in managing that portfolio. We're heading into fiscal '27 from a position of strength, with clear momentum throughout the business. That puts us in a good spot to keep building on it and to deliver sustainable long-term value for our customers, partners, and shareholders. Before handing things to Britt, I'd like to thank everyone at McKesson for their dedication and hard work — those contributions are at the heart of what we achieve. This also happens to be Britt's final earnings call. I want to express my gratitude for 20 years of exceptional leadership and service. As we'd planned, Britt will stay involved to support the team through the CFO transition, making sure there's continuity and stability for both the team and our operations. He'll additionally act as a strategic adviser, offering valuable perspective as we carry out our priorities, including the planned separation of the medical business. With that, Britt, over to you.

Britt Vitalone

executive
#4

Brian, thank you, and good afternoon to everyone. Fiscal 2026 represents another year of excellent financial performance. We delivered robust expansion across all of our core strategies, and at the same time we improved operating leverage through disciplined execution and portfolio actions that create lasting value for shareholders. For the entire year, our consolidated revenues reached $403 billion, which is a 12% increase. Adjusted operating profit grew 15%, coming in at $6.5 billion, while adjusted earnings per diluted share were up 18%, reaching $39.11. When you strip out the gains from McKesson Ventures investments during fiscal 2025, adjusted earnings per diluted share rose 20%, driven by strong execution across the business and continued momentum in our operating fundamentals. Importantly, these results exceeded the long-term growth targets that we are reaffirming today. I'll start by walking through how we did in the fourth quarter and across the full year, and after that I'll share what we expect for fiscal 2027. My comments will focus on adjusted figures unless I note otherwise. But before diving into the consolidated numbers, there are three things worth mentioning that only impacted GAAP results in the fourth quarter. The first involves net gains of $480 million from selling off our retail and distribution operations in Norway, which show up under other. With that deal, our divestiture activity in Europe is now complete. The second item: results for the quarter contained about $122 million in noncash adjustments tied to redeemable noncontrolling interests stemming from the Core Ventures acquisition within our oncology and multispecialty segment. Additionally, we logged a $182 million LIFO benefit tied to inventory accounting inside the North American Pharmaceutical segment. Moving on now to our consolidated results for the fourth quarter. Those results carried forward the same trend of steady operational excellence and disciplined growth we've been seeing. Diluted earnings per share reached $11.69, which is 16% higher than the prior year. That improvement was driven by demand spread broadly across the portfolio, among them continued growth in specialty pharmaceutical distribution throughout North American pharmaceutical, robust gains in oncology and multispecialty, and sustained momentum in biopharma solutions programs within Prescription Technology Solutions. Consolidated revenues climbed 6% to $96.3 billion, and gross profit increased 14% to $3.9 billion. Oncology and multispecialty drove the increase through provider expansion and specialty distribution, helped along by acquisitions and more prescriptions filled in North American pharmaceutical, though branded pharmaceuticals contributed less than before. Operating expenses rose 14%, reaching $2.1 billion, as oncology and multispecialty costs climbed, partly because of acquisitions made this year. Our ongoing emphasis on operating execution produced efficiency throughout our operations. Operating profit climbed 13% to $1.8 billion, powered by specialty distribution gains in oncology and multi-specialty and North American Pharmaceutical, plus stronger demand for access solutions in our Prescription Technology Solutions segment. Within corporate expenses, results took a hit from $15 million in pretax losses—equal to $0.09 per share—tied to equity investments held in the McKesson Ventures portfolio. On the interest side, we recorded $59 million, driven by larger average balances in the loan portfolio over the quarter. Our effective tax rate came in at 12.1% for the quarter, a figure that reflects $158 million in net discrete tax benefits stemming from liquidating our stake in a wholly owned affiliate. Diluted weighted average shares outstanding for the fourth quarter dropped 3% to $122.7 million, consistent with the repurchasing activity we've had underway. During the period we also kicked off a $2.25 billion accelerated share repurchase program, although it had no material impact on diluted weighted average shares for the quarter. Now moving to the fourth quarter results by segment, available on Slides 8 through 12, and starting with North American Pharmaceutical, revenues there hit $79.1 billion, up 3% from the prior year, powered by greater prescription volumes, especially ongoing momentum in Specialty Products. That gain was partly counterbalanced by reduced branded pharmaceutical revenue, due to price decreases on some manufactured products, which cut year-over-year revenue growth by roughly 3% for the quarter. GLP-1 distribution revenues came to $14 billion in the quarter, rising $2 billion, or 22%, versus last year. Sequentially, though, revenues dropped 4%. Crucially, neither the branded pricing reductions nor the quarter-over-quarter dip in GLP-1 volumes affected operating profit during the quarter. Segment operating profit rose 11%, reaching $980 million, while operating margins widened 9 basis points compared to the prior year. The results largely stemmed from growth in specialty product distribution, such as health systems, plus continued operating efficiency. Now looking at the Oncology and Multispecialty segment. Revenues climbed 35% to $12.7 billion, propelled by robust provider growth, broader specialty distribution, and acquisition contributions. PRISM and Core Ventures acquisitions added about 13% to that growth. Operating profit for this segment rose 53%, hitting $385 million. Without the acquisition effects, organic operating profit increased a solid 13%, highlighting strong core performance. Turning to Prescription Technology Solutions, we saw a 12% revenue increase, reaching $1.5 billion, driven by stronger prescription volumes across our third-party logistics and technology services businesses. Operating profit rose 13%, hitting $322 million, fueled by growing demand for access solutions. Now for Medical Surgical Solutions: revenue came in at $2.9 billion, up 1% from the previous year, primarily due to higher specialty pharmaceutical volumes, partially offset by softer results in the ambulatory care channel. Operating profit declined 5%, landing at $271 million. Looking at this quarter, we saw lower demand than a year ago for illness season offerings, including vaccines and testing. And finally, corporate expenses reached $209 million, reflecting both the McKesson Ventures portfolio losses we mentioned earlier and increased spending on technology infrastructure. Turning now to cash and capital deployment, which you'll find on Slide 13: throughout the fourth quarter we continued applying a disciplined approach to deploying capital that creates value. We ended the quarter holding $4 billion in cash and cash equivalents, with $9 billion in total liquidity. Free cash flow generated during the quarter was $3.2 billion, a figure that includes $185 million of capital expenditures. Those results stemmed from strong operating performance as well as the timing of working capital. Keep in mind, our free cash flow and working capital metrics can fluctuate from quarter to quarter, including depending on the weekday a quarter ends; we gave back $2.8 billion to shareholders in the quarter, with $2.7 billion via share repurchases and $101 million in dividends. That figure takes in $2.25 billion in buybacks conducted through an accelerated share repurchase program kicked off during March. During April, an extra $5 billion in repurchase authorization received approval from our Board of Directors, which lifted our overall authorization for buying back stock to roughly $7.7 billion as of April 2026. Through this move, we show even greater conviction regarding how sustainable our business is and how it can grow going forward. Looking at the big picture, fiscal 2026 turned in excellent performance, coming in above both the guidance we initially provided and our longer-range growth objectives. Across the full year, revenue increased 12% to $403 billion, operating profit was up 15% at $6.5 billion, and 3 of our 4 segments generated double-digit growth. If you factor in $101 million of net gains associated with McKesson Ventures in fiscal 2025, along with $51 million of net gains from the U.S. oncology network during the second quarter of fiscal 2026, operating profit rose 16% compared with the prior year. Our disciplined approach to deploying capital expanded our oncology multi-specialty growth pillar through the purchases of PRISM and Core Ventures, which added roughly 34% of the growth in segment operating profit. Both how integration is progressing and the results achieved so far give us reason for optimism.

Britt Vitalone

executive
#5

We kept up solid operational performance as well, and we improved efficiency further, which produced a 293 basis point gain in consolidated operating expenses measured as a share of gross profit versus the previous year. We managed that operating efficiency even while making focused investments and modernizing how we work through automation and AI-driven capabilities, and we expect those moves to speed up growth and generate efficiencies throughout the enterprise. Robust earnings growth fed into free cash flow of $5.4 billion. That figure contained $745 million of capital expenditures focused on distribution technology and infrastructure meant to underpin future growth. Free cash flow came in above our guidance range, powered by outstanding operating performance, working capital efficiencies and timing; we also kept showing an unmistakable dedication to giving capital back to our shareholders; during fiscal 2026, we returned $5.1 billion via share repurchases and dividends. From the beginning of fiscal 2020 through now, we have returned roughly $23 billion to shareholders, all while producing a 17% adjusted earnings CAGR, which shows what comes from combining consistently excellent operating performance with disciplined capital deployment. That excellent performance shows up in a return on invested capital of 34%, underlining how strong our operating model is and how well our capital allocation strategy works. Let me now move to our outlook. Over the past few years, the breadth of what we can do and our top-tier collection of assets in oncology and biopharma services have delivered steady value to our customers, partners, and shareholders. With that operating momentum behind us, along with a distinctive asset mix and a solid balance sheet, we're restating our long-term growth goals; we continue to anticipate long-term adjusted earnings per diluted share growth of 13% to 16%, driven by ongoing operating leverage and disciplined execution; we're also restating our long-term adjusted segment operating profit growth targets of 5% to 8% from North American Pharmaceutical, 13% to 16% for oncology and multi-specialty and 10% to 13% for Prescription Technology Solutions. We're heading into fiscal 2027 with a lot of momentum behind us. For that year, our guidance for adjusted earnings per diluted share sits at a range of $43.80 to $44.60 — that works out to growth of 12% to 14% compared with the prior year. To make the year-over-year picture clearer, there are two things from fiscal 2026 I want to flag, both of which I brought up before. The first is the Norway business, which we sold off in January of 2026 and which is reported inside other; it contributed $1 billion in revenues along with $74 million in operating profit. The second is the $51 million of gains we recorded during our second quarter tied to selling an equity investment in market decisions, which sits within the U.S. Oncology network. Excluding those two things, the earnings per diluted share guidance we've given for fiscal 2027 points to growth of 14% to 16%, putting it at the top of our long-term target range. Starting now with how we see the segments shaping up in fiscal 2027: for the North American Pharmaceutical segment, revenue should rise 4% to 8%, while operating profit should be up 5.5% to 9.5%; underlying this forecast are our large-scale distribution strengths, disciplined and excellent operations, and steady growth in prescription volumes. We expect the GLP-1 medication category to keep expanding. GLP-1 revenue climbed 27% during fiscal 2026, hitting $53 billion. As we look toward fiscal 2027, continued expansion in the category is what we anticipate, even if market dynamics cause some variability from one quarter to the next. Now, for Oncology and Multispecialty, revenue is projected to rise somewhere between 14.5% and 18.5% under our guidance, with operating profit increasing in the range of 13.5% to 17.5%. This outlook takes into account sustained growth taking place across oncology and multi-specialty platforms, driven by higher distribution volumes in multi-specialty from community-based settings. Additionally, it reflects the continued successful integration and expansion of PRISM Vision and Core Ventures. Both of these acquisitions are performing well and are expanding what we can offer to further care in oncology and retina settings. To pick up from what was said earlier, fiscal 2026 results included a $51 million gain tied to the sale of an equity investment and market decisions within the U.S. Oncology Network. Turning now to Prescription Technology Solutions, revenue growth is expected to land between 2.5% and 6.5%, with operating profit growth of 11% to 15%. Demand remains strong for our differentiated access and affordability solutions, especially for complex and specialty therapies such as GLP-1s. We're seeing sustained volume growth in the brands we support, helped by continued pharmaceutical innovation and increasingly complex care settings, which offer attractive long-term growth opportunities. As I mentioned before, revenue and operating profit trajectory in this segment is not linear. Several things can cause it to move from one quarter to the next. Those include how utilization trends develop, when new drugs launch and how that rollout unfolds, and how a product program's support needs change as it grows up — support might migrate to different services, or the program might end altogether. Product delays and supply dynamics matter too, as do payer utilization and formulary requirements. There are also the annual verification programs, which fall in our fiscal fourth quarter, plus how large our investments are and when we make them to support and grow our product portfolio. Taking everything together, our platform's strength, our disciplined execution and ongoing demand for our solutions give us confidence in where this business is headed over the long term. I want to bring everyone up to speed on Medical Surgical Solutions and where we stand in making it a standalone company. From the time we made the separation public, we've cleared a number of important hurdles. Operationally and legally, the business now stands on its own. Our carve-out financial statements have been audited and are finished. All the separation and transition service agreements we needed are now signed; in early April, we began putting an independent capital structure in place, starting with a $1 billion revolving credit facility and $1 billion of term loan A facilities issued. On top of that, we reached an agreement with Apollo Funds, which will pick up a minority stake of roughly 13% in Medical Surgical Solutions, a deal that puts the total enterprise value at about $13 billion. On top of that, Apollo has substantial expertise in handling intricate carve-outs as well as transactions in the public markets. Operating control, along with a majority stake in Medical Surgical, is going to stay with McKesson, and the segment's results will be consolidated in its financial reporting. Once the deal closes, Apollo's ownership stake will show up as noncontrolling interest. Our expectation is that the transaction will close after we receive regulatory approvals and satisfy the usual closing conditions. We also expect to issue up to $2.25 billion in additional term loans in the back half of the first quarter of fiscal 2027. Funds generated by both of these transactions will go toward settling intercompany agreements that are already in place with McKesson Corporation. Our plan is to put these funds to work consistent with our disciplined approach to capital allocation, mainly for buying back shares. Taken together, these deals will finish creating a standalone capital structure for the Medical-Surgical business. Looking at fiscal 2027, we're projecting revenue growth between 1% and 6%, with operating profit coming in flat to 4%. At Corporate, we expect expenses somewhere between $580 million and $640 million, since we'll keep putting money into technology innovation and efficiency. Now moving to items below the line; we're expecting interest expense in the $380 million to $420 million range. The total includes the fresh $1 billion term loan A arranged during April, along with a forthcoming $2.25 billion in additional term loans that back the carve-out of the Medical Surgical Solutions segment; we anticipate income attributable to noncontrolling interest will come in somewhere between $295 million and $325 million. Compared with the prior year, this increase is driven largely by the minority stake Apollo Funds is expected to take in Medical Surgical.

Britt Vitalone

executive
#6

And then, looking ahead to the complete year, we expect our effective tax rate to land somewhere between 17% and 19%. Now, turning to cash flow and how we're deploying capital. When we look at fiscal 2027, we're expecting free cash flow to come in at roughly $4.5 billion to $4.9 billion, which speaks to ongoing operational efficiency and a disciplined approach to managing working capital. In line with how we think about capital allocation, our plan is to buy back about $5 billion worth of shares during fiscal 2027. This stepped-up activity is made possible by putting to work the proceeds from the Medical Surgical financing related to the Apollo minority investment. Because of that, we expect weighted average diluted shares outstanding to fall somewhere in the range of 116 million to 118 million for the entire year. So, to close out our fiscal 2027 guidance: we're looking for revenue growth between 5% and 9%, along with adjusted operating profit growth of 8% to 12%. And for fiscal 2027, we expect earnings per diluted share to be between $43.80 and $44.60. When it comes to the cadence of earnings per share, we think it'll be broadly comparable to fiscal 2026 when you look at it from a first half versus second half standpoint, with some quarter-to-quarter variability driven in part by when discrete tax items were recognized in fiscal 2026. In summary, we had a strong year, powered by disciplined execution across our core businesses and an unwavering focus on creating long-term value. Our balance sheet and our ability to generate cash give us the flexibility to invest in our strategic priorities while consistently returning capital to shareholders. We stay confident in our outlook and are well positioned to execute our strategy and deliver sustainable growth. On a personal note, this marks my final earnings call as McKesson's CFO. Serving in this role has been a privilege, and so has partnering with an exceptional leadership team and finance organization. I take pride in what we've accomplished together, and I feel confident about what's ahead. Our fundamentals are strong, our strategy is clear, and we're well positioned to deliver sustainable long-term value creation. After I retire, I'll keep supporting McKesson in an advisory role to help ensure a smooth transition and preserve our current momentum. I'd like to thank all of you for your continued support of McKesson. And with that, let's move to the Q&A session.

Allen Lutz

analyst
#7

To start, Brett, congratulations on retiring. Everyone here will miss having you around. Now, regarding RxTS, when I look at the revenue growth for fiscal 2017, 2.5% to 6.5%, my sense is that this might be somewhat slower than the pace we've seen during the last few years. That said, this segment contains many different components. Is the deceleration attributable to the 3PL operation, or does it originate somewhere else within the business? Also, when considering the GLP-1 piece of the prior authorization operation, you noted that GLP-1 revenue fell 4% from one quarter to the next in the distribution business. What do you anticipate for GLP-1 growth in that prior authorization operation throughout fiscal '27?

Britt Vitalone

executive
#8

Appreciate that question, Allen. Let me spend a moment on revenue and prescription technology; this is something we've discussed across the last several quarters. When you consider how revenue is composed within that segment, as we've discussed for the last several years, the 3PL piece accounts for approximately 55% of total revenue. And as we've discussed, that operation can fluctuate substantially between quarters or between years, depending on various factors. It might be the timing of product launches, for products we could support under those 3PL programs. It might be the timing of program launches for products that are launching. Every one of those things can cause considerable variability in the revenue portion of that 3PL business. And as I said, it truly is the dominant revenue component for that segment. When you examine the operating profit momentum, which our guidance for next year places really at the upper end of the long-term target range, that really reflects the excellent recognition, support, and demand we're receiving for the programs of our technology services, chiefly our access programs, which include GLP-1. So I believe that's a strong signal that our programs within our Technology Services aspect keep enjoying robust demand and are generating a great deal of value. And so I think the operating profit we've cited here reflects that well.

Lisa Gill

analyst
#9

Britt, all the best to you in retirement. I'd really like to explore oncology and multispecialty from the guidance angle. Could you discuss what portion of revenue and adjusted operating profit is organic versus inorganic? What's the current status of a few of those acquisitions you completed, and how will they add to 2027? Also, regarding what occurred this quarter, were there any weather-related effects? We're aware you had mentioned weather, but was there any impact? And is there anything else you'd highlight as we consider fiscal '27, specifically for oncology and multispecialty?

Britt Vitalone

executive
#10

Lisa, I appreciate the question. Let me begin with weather, since that's one we've fielded quite a bit over the past several months. As Brian said in his remarks, I can confirm we saw some weather effects in January. Yet across the entire quarter, weather had no effect on our operations. Any demand effects during that roughly two-week stretch in January were recovered inside the quarter. So that isn't something we've discussed, and it isn't something we're discussing today. Turning to the oncology and multi-specialty segment, we will be lapping both the PRISM and Core Ventures acquisitions that closed in the first quarter of last year; and at the underlying level, as I noted a few times in my script, organic growth for that segment has been running at approximately 13%. Now, looking at the guide, keep in mind, as I pointed out a few times here, that last year we had $51 million of gains in the second quarter tied to the sale of an equity investment and other market actions. So the segment's organic performance is in fact somewhat better than what the guide shows. And we consider the guide to be strong, and it actually sits at the upper end of the long-term target range. So we feel good that the acquisitions are doing well. The integrations are progressing well. And as we lap that, the organic growth rate will land right in the middle of that long-term target range.

Brian Tyler

executive
#11

Correct. I'd also mention that we're still aiming to expand the provider network, whether by bringing oncologists into the practices we already have or through a pipeline of targets we consider appealing. Clearly, predicting when those will come through isn't so simple, but we remain in active talks. We expect that to remain a component of how this business grows.

Erin Wright

analyst
#12

Thank you. I'd like to dig into what you're observing within the core North American Pharmaceutical segment specifically. Regarding underlying utilization trends, what assumptions are baked into the guidance? In your prepared remarks, I believe you described it as stable. Also, for the quarter, last quarter I think you highlighted specialty products in a broader sense, while this quarter you're pointing specifically to specialty products going to health systems. Could you share what you're seeing there and what carries forward into 2027?

Britt Vitalone

executive
#13

Yes. I appreciate the question. On utilization, what we've observed is stability, meaning that the year-over-year increase in utilization has held fairly steady across a number of quarters now. It keeps growing, though at a very consistent pace over roughly the past 2, 3 years, I'd say. That's something we built into our guidance as one of the core foundational elements. Specialty remains the area where the greatest innovation is occurring and where growth outpaces every other category. Our position there is strong. At our Investor Day, we discussed the size and scale of our specialty business, on both the distribution side and the multi-specialty side, which remains a strength for us. I brought up health systems. For many years we've held a strong position in health systems. Our value proposition there continues to be strong. And specialty products within health systems have certainly been valuable to us, and we deliver a great deal of value to our customers, so the growth we're seeing is good. Growth in fiscal '26 was very strong. We anticipate that growth carrying forward into '27. As for our guide, we once again positioned it at the upper end of the range, the long-term target range we previously provided. So we're feeling good that this momentum stays strong.

Brian Tanquilut

analyst
#14

And Britt, I want to thank you for the collaboration we've shared throughout these years. So, reflecting on what was said about GLP, I'm grateful for how you addressed the earlier questions, but regarding the LRP, what's your thinking on — or how ought we approach, let's say, the durability of demand within the Access Solutions part of the business, particularly as it ties to GLPs?

Britt Vitalone

executive
#15

Yes. Excellent question. What I'd say is that on the distribution side and also on our Technology Solutions side, growth has really been robust across the past 3 years when viewed from a distribution standpoint. Once more, distribution revenue growth has been running in the mid-20% range over the last several years. On a sequential basis, it declined during the fourth quarter, which I mentioned, yet it still expanded 22% for that quarter; and the offerings we bring, covering prior authorization along with affordability, remain in high demand and are generating considerable value. Our teams have introduced adjacent products to many additional services that go past simply basic prior authorization. And we continue to witness quite strong growth in that area. I believe the operating profit growth in the segment demonstrates this, along with the guidance we've established for next year; so the category keeps expanding, and the need for what we offer, including prior authorization and certain affordability products, remains solid.

Michael Cherny

analyst
#16

Britt, best of luck with your golf game moving forward. Perhaps we could discuss the MSO side a bit, particularly as you bring Core Ventures onboard within the Florida Cancer business. When you consider the wrap services you currently offer in relation to oncology overall — how is the pipeline evolving regarding extra services you're able to develop as your scale increases? And where do opportunities exist to keep expanding, be it in oncology or elsewhere, across the full range of services that could drive additional revenue and profit streams.

Brian Tyler

executive
#17

Michael, I'll take this one. As I said a moment ago, we believe there's still space to grow simply by broadening our provider base. A portion of that growth depends on the compelling value proposition we offer providers, which includes investments we're making within the practices themselves, such as ambient scribe, improving the physician work experience by allowing them to concentrate more on patient care and less on administrative tasks, which we believe helps tackle burnout. That draws people into our network, whether individuals or other practices; so that remains, in my view, a crucial element of the growth algorithm. Beyond that, we believe technology can help us run the business more efficiently while also extracting richer and deeper insights that support and scale our Ontada business; and, honestly, to keep expanding SCRI's capacity to involve more physicians more deeply in clinical trial recruitment; so as these technologies develop and we keep leveraging them more effectively, we'll keep discovering ways to strengthen both our value proposition for physicians and for manufacturers, which generates this kind of virtuous cycle.

Elizabeth Anderson

analyst
#18

Congratulations on your retirement, Britt, and I'm eager to hear more about that. Regarding your — I believe what's been raised by folks on this quarter's earnings calls is the situation with biosimilar transitions. And clearly, you've helped educate us regarding how Part D biosimilars differ from the Part B biosimilar waves still ahead. How are you collaborating with your customers to get ahead of some of these changes in others within the Part D arena? And how should we consider that being reflected in your guidance for 2027?

Britt Vitalone

executive
#19

Well, I'll begin, and of course, Brian can chime in. We've been talking about this for a number of years now: our view is that biosimilars hold a lot of promise going forward, and honestly, everybody in the chain comes out ahead. For our providers, these products give them the ability to make a clinical call and decide which items fit their protocols; patients usually pay less, and for a distributor they're more efficient. On the distributor side of the economics, it genuinely matters whether a drug falls under Part B or Part D, along with what services McKesson is able to deliver and how many of them; so on that point, nothing has really shifted. What we do is supply services to our providers. The clinical decisions about which products they wish to use are theirs to make. Beyond that, when we're able to offer things like GPO services or other kinds of handling services, it only improves the whole experience — it brings costs down for providers and patients alike. So our view is that this area is expanding. Right now we have 89 that have gotten approval, and 72 have launched. So that keeps expanding, it keeps bringing more options and reduced costs, and we believe our position is strong when it comes to delivering those services.

Brian Tyler

executive
#20

Biosimilars get distributed by us across every segment we serve — hospitals, retail, pharmacy, and of course community — while the Part D channel stands out as the one we find most appealing.

Glen Santangelo

analyst
#21

Brian, may I quickly piggyback on the point Elizabeth raised a moment ago? My understanding is you described the Part B channel as the one holding the most interest for you. If I misheard, my apologies. What I believe worries investors most is this: looking ahead across the coming several years, over 1/3 of the oncology market will plainly be affected either by the IRA or by a biosimilar shift. So as the prices of those oncology medications decline — Britt, if I caught your remarks correctly, you called it a win-win-win for the provider. Yet if reimbursement is tied to ASP and the drug's price is declining, does the practice actually come out ahead? Then, Brian, I struggle to work out the margin effect that could hit your distribution business because of the lower price. Really, we're just attempting to grasp that biosimilar transition as it plays out in your specialty business. And whether you genuinely believe it will boost your longer-term operating profit. Apologies for the rambling.

Brian Tyler

executive
#22

You win the award for the lengthiest question, though it was well put. Regarding the distribution side, I believe we've stated that for us biosimilars will land somewhere between generics and brands, and our view on that hasn't changed. Things get somewhat more intricate within the community setting, the RB setting; we have this ASP dynamic at play. Typically — based on our early experience with these products at the time of their initial launch — this benefits the practice, as Britt mentioned; after that, you must ensure that ASP holds up; and we've observed biosimilars entering the market and exiting it. The single edge we possess, though, stems from network effects — especially in U.S. oncology, and we believe eventually in retinology — is our ability to push adoption toward these biosimilars, or toward the innovator drug, in a manner that's more consistent and faster. That generates value for the manufacturer, which they're prepared to pay the GPO and the distribution business for.

Daniel Grosslight

analyst
#23

First, I want to congratulate Britt on retiring. It's been great working with you over these past few years. I'd like to focus a bit on free cash flow and how you're prioritizing capital deployment for fiscal '27. Based on the guidance, it looks like free cash flow takes a modest step down — about a 13% decline compared with last year — despite AOP rising 10%. So my question is: what's driving that weaker conversion in fiscal '27? Fiscal '26 was obviously quite strong. And on capital deployment priorities, it doesn't look like you're pulling back on business investment, and share repurchases remain robust. I'd like to hear your thoughts on M&A plans for fiscal '27. Also, are your M&A priorities shifting at all, or is it more about which targets are out there?

Britt Vitalone

executive
#24

Sure. I appreciate you asking both. I'll take the first one. Regarding our '27 cash flow guidance, our confidence is high. Looking back across the past few years, the outlook we shared today remains quite robust; we're producing a substantial amount of free cash flow. And on the investment side — like you said, we continue putting money into the business at a much faster pace so we can improve operating efficiency and support growth down the road. During my prepared comments about 2026, I noted that timing played a role in how much cash we generated during Q4. And honestly, timing comes up constantly — things like which weekday a quarter wraps up on, or which weekday a big manufacturer payment lands on, maybe a Tuesday or Wednesday right at quarter's end. So working capital fluctuations do move things around from one quarter to the next. Still, when you zoom out across a longer stretch, the moving average for cash flow is climbing, and it matches up well with what we've delivered operationally. Regarding how we deploy capital, our approach remains the same. Brian and I have had many conversations about how this really comes down to three main pillars, and growth is where it all begins. Keeping the business expanding—and doing so in line with our strategy—remains our top focus. When we can locate chances to push our growth pillars forward while generating solid financial returns, that's what we prioritize. The second pillar is that shareholders will always receive capital back from us. As earnings grow, our dividend grows too, and it keeps climbing. On top of that, we intend to keep returning capital through buybacks of shares. Looking back over the last few years, we feel we've been pretty inventive in how we deliver value. Then, finally, everything rests on preserving our exceptionally solid investment-grade credit rating. Given how strong our balance sheet is, I believe we've managed that really well. So that remains a constant priority for us. Again, stepping back to consider it, we want to grow the business both organically and inorganically, while simultaneously continuing to return capital to our shareholders. Clearly, we face a unique circumstance as we separate the medical business. We're raising some funds that we can deploy in a value-creating manner, and for modeling purposes in our outlook, we've allocated that toward share repurchases. But like we've told you all along, if growth chances come up that fit what we're trying to do and come with solid financial payoffs, we're able to move capital out of buybacks and into growth, or flip that direction. Being extremely efficient with the balance sheet is always our goal. And my sense is that when you look at how much of our cash flow has gone back out, whether via M&A or to shareholders, that figure is pretty high. So our balance sheet really is very efficient, and our strategies are robust. They've generated substantial value, and honestly, when we think about '27, nothing has changed.

Charles Rhyee

analyst
#25

Congratulations, Britt. Best wishes for whatever comes next. If I could return to the North America pharma guidance — clearly you addressed the revenue guidance, and my read is that this likely reflects the ongoing effect of pricing shifts in the market. First, is that the correct interpretation? Then the second piece: looking at the AOI growth, it's actually somewhat higher than the LRP targets of 5% to 8%. Could you perhaps walk us through what's driving that stronger than anticipated result, and, like with biosimilars, there are many small molecule generics on the way — maybe frame how that could be a tailwind either this fiscal year or in future fiscal years.

Britt Vitalone

executive
#26

Yes. Thanks for asking. Let me start with how things look in North America on the top line. As we consider the shift from 2026 into 2027, a few factors are working against us. First, one quarter's worth of sales came from a major client we had added during the prior year, so we're now comparing against that. On top of that, three quarters of our revenue were connected to Rite Aid. This doesn't hit earnings, or if it does, only marginally. On the top line, though, there's the fact that three quarters of Rite Aid-related revenue are now in the comparison base. And like I mentioned earlier, during Q4 we did feel some impact from manufacturers cutting branded prices, and going forward that will be a full twelve months of those declines. So once you factor all of that in, plus the organic growth underneath — the top-line expansion of the business — it's actually pretty impressive relative to history; and on the adjusted operating profit growth side, our positioning feels very strong. Specialty pharmaceuticals, as I noted, continue to expand at a healthy clip; we hold a scaled spot in that market and are set up well; our operating efficiency is excellent. When it comes to overall operating efficiency, I mentioned that operating expenses measured against gross profit dropped by 293 basis points during FY '26. A significant portion of those gains stems from what we've put into our network, along with spending on infrastructure, and a great deal of that is benefiting the North American segment. So once again, I'd say that segment is still robust. Momentum there is solid, and our '27 guidance gives us confidence.

Brian Tyler

executive
#27

All right, and thanks to each of you. I'm grateful that you've all joined us on today's call, and for the thoughtful questions you bring, as you always do. My thanks go out to our operator for making this work. With a truly strong fiscal '26 now behind us, I want to express appreciation to the 43,000 people at McKesson for the dedication they show daily in moving our mission forward; the momentum we see throughout the enterprise makes us pleased. By drawing on our differentiated portfolio of health care service solutions, we're eager to keep executing our strategy and creating value for our shareholders, for our customers, and for their patients. And lastly, Britt, a word of thanks to you for your commitment and your friendship. The past 20 years have been an enormous pleasure.

Britt Vitalone

executive
#28

Thank you.

Brian Tyler

executive
#29

Thanks, everybody. Have a great evening.

Operator

operator
#30

We appreciate you being part of today's conference call. At this point you're free to hang up, and we hope the rest of your day goes wonderfully.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete McKesson Corporation transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to McKesson Corporation earnings transcripts and 131,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in McKesson Corporation or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.